Dear AVAC supporter,

Twenty-five years ago, AVAC was founded to speed the development of preventive HIV vaccines. After a decade of advocacy for increased investments and smart decision-making to advance vaccine research and development, we leveraged our work and credibility to respond to initial controversies related to oral pre-exposure prophylaxis (PrEP) research and expanded our mandate across the larger HIV prevention research landscape. Today, we continue to focus on accelerating ethical research and development as well as implementation and delivery of new biomedical prevention options as part of a comprehensive response to HIV. AVAC works across the “research-to-rollout” continuum in solidarity with individuals and groups most impacted by HIV.

We believe the struggle to end the AIDS epidemic is, above all, a struggle to provide truly effective HIV prevention. This means re-doubling our efforts and continuing to advocate for scientific research to develop long-term solutions, such as HIV vaccines and a functional cure.

Our financial position reflects the successful past and future sustainability of AVAC. In 2018, our total revenues increased by $8.7 million, or 64% from the prior year. At the same time, our total net assets increased $2.7 million, or 35%. These numbers clearly show we are well-positioned for the future. We continue to receive strong, multi-year support from major funders and governments, continually educate and enhance our professional staff, and are ready to face new challenges and opportunities as they arise. We are proud of our sustainable growth and our impact on the HIV epidemic.

As AVAC has grown, we’ve remained committed to the values on which we were founded. Advocates and community members must continue to play a leading role in defining the HIV research and implementation agendas. It will take all of us working together to end AIDS.

Maureen Baehr

Maureen Baehr, Board Treasurer